This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

INFANRIX Logo

Prescribing Information

Coding for INFANRIX

Here you’ll find vaccine product codes and some common administration codes associated with immunization using INFANRIX. Select another vaccine here.

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

Description: INFANRIX is available in 0.5-mL single-dose, disposable, prefilled TIP-LOK syringes (Luer Lock syringes) packaged without needles.1

Dosage: 0.5 mL1

Coding for INFANRIX

CPT Code

90700

ICD-10-CM Code2*

Z23
MVX Code3 SKB
CVX Code4 20

NDCs† (Syringe in package of 10)

Syringe

NDC 58160-810-43

Outer Carton

NDC 58160-810-52
Tip

Tip

To promote accuracy, always consult the most current Prescribing Information or product packaging when documenting NDCs.

INFANRIX CPT Code – Immunization Administration Codes5‡

90460:

Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered 

 

+90461:

Each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)

 

90471:

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)

+90472:

Each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Tip

Tip

If reporting multiple vaccine administrations given to a patient through age 18 on the same date along with counseling by a qualified healthcare professional, report one administration code (90460) for each vaccine administered

If a vaccine has multiple components, then 90460 should be reported once in conjunction with 90461 for each additional vaccine/ toxoid component contained within that vaccine.6

Diagnosis Codes

Z23 is the ICD-10-CM code used when reporting an encounter for immunization for all vaccines given within the encounter. In some instances, additional ICD-10-CM coding may be needed. 

See all code types

GSK Codes Summary Sheet

Get a PDF of the most current CPT, CVX, MVX, and NDC codes for GSK vaccines.

Download

Questions?

Find answers to frequently asked questions, along with additional resources, to guide you to the information you need.

Get help

  •   *ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.2
  •   †Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.7 For example, when reporting NDC 58160-820-11 to TRICARE, it becomes NDC 58160-0820-11.
  •    ‡Adapted from the American Medical Association, CPT 2024 Professional Edition, Current Procedural Terminology (CPT), 2023.

References:

  1. Prescribing Information for INFANRIX.
  2. 2024 ICD-10-CM official guidelines for coding and reporting. Centers for Medicare and Medicaid Services. Updated April 1, 2024. Accessed May 30, 2024. https://www.cms.gov/files/document/fy-2024-icd-10-cm-coding-guidelines-updated-02/01/2024.pdf
  3. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. Centers for Disease Control and Prevention. Accessed May 30, 2024. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx
  4. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. Centers for Disease Control and Prevention. Accessed May 30, 2024. https://www2a.cdc.gov/vaccines/IIS/IISStandards/downloads/cvx_list.pdf
  5. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listing) long descriptors. American Medical Association. Updated May 23, 2024. Accessed May 30, 2024. https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf
  6. Bright futures coding for pediatric preventive care 2022. American Academy of Pediatrics. Accessed May 30, 2024. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf
  7. Office injectable guidelines, National Drug Code (NDC) pricing and filing tips. Humana Military. Accessed May 30, 2024. https://www.humanamilitary.com/provider/claims/injectables#nucleustabs-ee21c6fea3-item-098209c56a-tab

Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.

Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

Indication for INFANRIX

INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years of age (prior to seventh birthday).

Important Safety Information for INFANRIX

  • Contraindications for INFANRIX are: severe allergic reaction (eg, anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of INFANRIX; encephalopathy within 7 days of administration of a previous pertussis-containing vaccine; progressive neurologic disorders
  • The decision to give INFANRIX should be based on potential benefits and risks if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, or if adverse events (ie, temperature ≥105oF, collapse or shock-like state, persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours after vaccination; seizures within 3 days after vaccination) have occurred after receipt of a pertussis-containing vaccine
  • The tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions. Please check the carton
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination with INFANRIX
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination with INFANRIX should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination
  • In clinical studies, common adverse reactions were injection-site reactions (pain, redness, and swelling), fever, drowsiness, irritability/fussiness, and loss of appetite 
  • Vaccination with INFANRIX may not result in protection in all vaccine recipients

Please see full Prescribing Information for INFANRIX.